Loading clinical trials...
Loading clinical trials...
A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma
This is a one-year study to look at the safety of a dry powder inhaler with albuterol. After a one-week run in, for the first 3 months subjects will use an inhaler with either albuterol or a dummy drug at regular times four times a day. Then for the last nine months of the study, all subjects will be given the albuterol dry powder inhaler and will use it only when needed to help with breathing problems. Subjects will need to keep a daily diary (both paper and electronic) throughout the study recording any inhaler use and health problems. There will be visits to the study doctor about once a month for a year. This study is intended to show that the albuterol dry powder inhaler works well and is safe for use over a long period of time.
The Sponsor terminated this study due to the need for a modification to the Spiromax device utilized in this study; the problem identified has no impact on patient safety. Exposure ranged from 3 to 49 days with the majority of subjects receiving ≤30 days of double-blind treatment.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Teva Clinical Study Site
Scottsdale, Arizona, United States
Teva Clinical Study Site
Los Angeles, California, United States
Teva Clinical Study Site
San Diego, California, United States
Teva Clinical Study Site
Centennial, Colorado, United States
Teva Clinical Study Site
Denver, Colorado, United States
Teva Clinical Study Site
Miami, Florida, United States
Teva Clinical Study Site
Gainesville, Georgia, United States
Teva Clinical Study Site
Louisville, Kentucky, United States
Teva Clinical Study Site
Wheaton, Maryland, United States
Teva Clinical Study Site
Minneapolis, Minnesota, United States
Start Date
October 1, 2010
Primary Completion Date
December 1, 2010
Completion Date
December 1, 2010
Last Updated
May 20, 2015
331
ACTUAL participants
Placebo Spiromax
DRUG
Albuterol Spiromax
DRUG
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07219173